GB201900529D0 - Bicyclic peptide ligands specific for CD38 - Google Patents

Bicyclic peptide ligands specific for CD38

Info

Publication number
GB201900529D0
GB201900529D0 GBGB1900529.7A GB201900529A GB201900529D0 GB 201900529 D0 GB201900529 D0 GB 201900529D0 GB 201900529 A GB201900529 A GB 201900529A GB 201900529 D0 GB201900529 D0 GB 201900529D0
Authority
GB
United Kingdom
Prior art keywords
peptide ligands
ligands specific
bicyclic peptide
bicyclic
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1900529.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Priority to GBGB1900529.7A priority Critical patent/GB201900529D0/en
Publication of GB201900529D0 publication Critical patent/GB201900529D0/en
Priority to US17/422,940 priority patent/US12516084B2/en
Priority to EP20701837.5A priority patent/EP3911365A1/en
Priority to PCT/GB2020/050073 priority patent/WO2020148529A1/en
Priority to CN202080019655.7A priority patent/CN113543813B/zh
Priority to JP2021540842A priority patent/JP7645801B2/ja
Priority to JP2024185776A priority patent/JP2025023938A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
GBGB1900529.7A 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38 Ceased GB201900529D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB1900529.7A GB201900529D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38
US17/422,940 US12516084B2 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for CD38
EP20701837.5A EP3911365A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for cd38
PCT/GB2020/050073 WO2020148529A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for cd38
CN202080019655.7A CN113543813B (zh) 2019-01-15 2020-01-15 Cd38特异性的双环肽配体
JP2021540842A JP7645801B2 (ja) 2019-01-15 2020-01-15 Ｃｄ３８に特異的な二環式ペプチドリガンド
JP2024185776A JP2025023938A (ja) 2019-01-15 2024-10-22 Ｃｄ３８に特異的な二環式ペプチドリガンド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1900529.7A GB201900529D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38

Publications (1)

Publication Number Publication Date
GB201900529D0 true GB201900529D0 (en) 2019-03-06

Family

ID=65528180

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1900529.7A Ceased GB201900529D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38

Country Status (6)

Country Link
US (1) US12516084B2 (https=)
EP (1) EP3911365A1 (https=)
JP (2) JP7645801B2 (https=)
CN (1) CN113543813B (https=)
GB (1) GB201900529D0 (https=)
WO (1) WO2020148529A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642514A (en) 1946-08-10 1953-06-16 American Cyanamid Co Ion exchange process with magnetic ion exchange resins
GB1239978A (en) 1968-07-15 1971-07-21 Permutt Company Ltd Ion-exchange processes
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
JP2001505194A (ja) 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー 分枝ペプチド・リンカー
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
EP1115888B1 (en) 1998-09-24 2008-03-12 Indiana University Research and Technology Corporation Water-soluble luminescent quantum dots and bioconjugates thereof
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
HUE026218T2 (en) 2002-02-21 2016-05-30 Inst Virology MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
WO2004052404A2 (en) 2002-12-12 2004-06-24 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
CA2505655C (en) 2004-04-28 2013-07-09 Warren Chan Stable, water-soluble quantum dot, method of preparation and conjugates thereof
WO2006078161A1 (en) 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
US7989590B2 (en) 2005-03-22 2011-08-02 Rohto Pharmaceutical Co., Ltd Peptides that increase collagen or hyaluronic acid production
EP1928912A4 (en) 2005-09-07 2010-02-24 Medimmune Inc EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
KR20090053863A (ko) 2006-09-15 2009-05-27 지멘스 메디컬 솔루션즈 유에스에이, 인크. 인테그린에 대한 이미지화제로서 클릭 화학반응-유래된 시클로펩티드 유도체
CN101232326B (zh) 2007-01-22 2012-01-11 中兴通讯股份有限公司 用于无源光网络系统的动态带宽分配装置及其实现方法
JP2010526091A (ja) 2007-04-30 2010-07-29 インテザイン テクノロジーズ， インコーポレイテッド 癌の処置のための生物学的な標的基の改変
US20100254996A1 (en) 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
WO2009097397A2 (en) 2008-01-30 2009-08-06 Dyax Corp. Metalloproteinase binding proteins
CN101497878B (zh) 2008-01-30 2012-11-07 房学迅 特异性高效亲和膜ⅰ型基质金属蛋白酶(mt1-mmp)的多肽、蛋白及其应用
EP2653545A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
CA2717060C (en) 2008-02-27 2016-11-01 Avigdor Scherz Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
FR2932189A1 (fr) 2008-06-10 2009-12-11 Commissariat Energie Atomique Biopuces pour la detection de l'activite enzymatique d'une enzyme protease
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
EP2433322A4 (en) 2009-05-19 2015-11-04 East Penn Mfg Co COMPOSITE CURRENT COLLECTOR AND RELATED METHODS
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
US9073974B2 (en) 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
US20130072598A1 (en) 2011-03-18 2013-03-21 Board Of Regents Of The University Of Nebraska Thermoplastics from Distillers Dried Grains and Feathers
PL2764140T3 (pl) 2011-10-07 2018-04-30 Bicyclerd Limited Modulacja specyficzności polipeptydów ustrukturyzowanych
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
EP2898085B1 (en) 2012-09-24 2019-01-23 MedImmune Limited Cell lines
US9587001B2 (en) 2012-10-19 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
US20140274759A1 (en) 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
US9868767B2 (en) 2013-05-23 2018-01-16 Ohio State Innovation Foundation Chemical synthesis and screening of bicyclic peptide libraries
NZ718283A (en) 2013-09-25 2022-05-27 Cytomx Therapeutics Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
ES2715379T3 (es) 2013-10-28 2019-06-04 Bicyclerd Ltd Novedosos polipéptidos
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
DK3140653T3 (da) 2014-05-08 2022-06-20 Novodiax Inc Direkte immunhistokemianalyse
JP6807831B2 (ja) 2014-05-21 2021-01-06 エントラーダ セラピューティクス，インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
CN115093463A (zh) 2014-09-30 2022-09-23 波利弗尔股份公司 β-发夹肽模拟物
WO2016065258A1 (en) 2014-10-24 2016-04-28 Research Corporation Technologies, Inc. Small antibody-like polypeptides that bind to epha2 receptor
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
AU2015339012B2 (en) 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
US10335495B2 (en) 2014-12-04 2019-07-02 Celgene Corporation Biomolecule conjugates
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
WO2016171272A1 (ja) 2015-04-22 2016-10-27 三井化学株式会社 関節用サポーター部を備える衣類、及び膝用サポーター
WO2016171242A1 (ja) 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
CN107810190A (zh) 2015-04-28 2018-03-16 洛桑联邦政府综合工科学校（Epfl) 酶活化因子XII (FXIIa)的新型抑制剂
US10844111B2 (en) 2015-05-06 2020-11-24 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type III domains
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
US9963495B2 (en) 2015-10-27 2018-05-08 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
GB201600911D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
GB201600903D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Peptide derivaties
US10765625B2 (en) 2016-03-15 2020-09-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
JP2019512477A (ja) 2016-03-16 2019-05-16 メリマック ファーマシューティカルズ インコーポレーティッド エフリン受容体ａ２（ｅｐｈａ２）のナノリポソーム標的化及び関連する診断
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
BR112018071465A2 (pt) 2016-04-20 2019-02-05 Hangzhou Dac Biotech Co Ltd derivados de toxinas de amanita e sua conjugação a uma molécula de ligação celular
EP3445788B1 (en) 2016-04-22 2022-01-19 Alligator Bioscience AB Novel bispecific polypeptides against cd137
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
BR112018074453A2 (pt) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
EP3544621A1 (en) 2016-11-27 2019-10-02 BicycleRD Limited Methods for treating cancer
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
US20190389907A1 (en) 2016-12-23 2019-12-26 Bicycletx Limited Peptide ligands for binding to mt1-mmp
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2018222987A1 (en) 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US11572370B2 (en) 2018-01-08 2023-02-07 Biohaven Therapeutics Ltd. CD16A binding agents and uses thereof
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
EP3774851A1 (en) 2018-04-04 2021-02-17 BicycleTX Limited Heterotandem bicyclic peptide complexes
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810325D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
SG11202104356VA (en) 2018-10-30 2021-05-28 Bicyclerd Ltd Bt1718 for use in treating cancer
WO2020120984A1 (en) 2018-12-13 2020-06-18 Bicycletx Limited Bicyclic peptide ligands specific for mt1-mmp
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
US10882987B2 (en) 2019-01-09 2021-01-05 Nova Chemicals (International) S.A. Ethylene interpolymer products having intermediate branching
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
SG11202110828UA (en) 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TWI869398B (zh) 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20220275053A1 (en) 2019-08-13 2022-09-01 Bicycletx Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
SMT202500247T1 (it) 2019-10-03 2025-09-12 Bicycletx Ltd Complessi peptidici eterotandem biciclici
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
WO2021074647A1 (en) 2019-10-16 2021-04-22 Bicyclerd Limited Methods for treating cancer
MX2022006001A (es) 2019-11-27 2022-10-27 Bicycletx Ltd Ligandos de peptidos biciclicos especificos para el receptor 2 tipo a de efrina (epha2) y usos de los mismos.
IT202000001231A1 (it) 2020-01-22 2021-07-22 Celery S R L Nuovi ceppi di batteri lattici, composizione alimentare che li comprende, preparazione di tale composizione
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
US20230181749A1 (en) 2020-05-20 2023-06-15 Bicycle TX Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
CN115698720A (zh) 2020-06-12 2023-02-03 拜斯科技术开发有限公司 特征在于促红细胞生成素产生肝细胞受体a2(epha2)的过表达的疾病的治疗
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
CA3186504A1 (en) 2020-08-17 2022-02-24 Stephen J. Blakemore Bicycle conjugates specific for nectin-4 and uses thereof
US20240083945A1 (en) 2021-01-08 2024-03-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
DK4274838T3 (da) 2021-01-08 2024-10-21 Bicycletx Ltd Bicykliske peptidligander, der er specifikke for NK-celler
AU2022206577A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
CN118103075A (zh) 2021-09-03 2024-05-28 拜斯科技术开发有限公司 双环肽毒素偶联物及其中间体的合成
KR20240100420A (ko) 2021-11-16 2024-07-01 바이사이클티엑스 리미티드 암을 치료하기 위한 방법

Also Published As

Publication number Publication date
US12516084B2 (en) 2026-01-06
CN113543813A (zh) 2021-10-22
EP3911365A1 (en) 2021-11-24
US20220064218A1 (en) 2022-03-03
CN113543813B (zh) 2024-03-29
JP2025023938A (ja) 2025-02-19
JP7645801B2 (ja) 2025-03-14
JP2022517040A (ja) 2022-03-03
WO2020148529A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
GB201900530D0 (en) Bicyclic peptide ligands specific for CD38
ZA202100442B (en) Bicyclic peptide ligands specific for nectin-4
GB201900529D0 (en) Bicyclic peptide ligands specific for CD38
IL290089A (en) Heterotandem bicyclic peptide complexes
IL287881A (en) Ox40-specific bicyclic peptide ligands
HUE072242T2 (hu) Heterotandem biciklusos peptidkomplexek
GB201900526D0 (en) Bicyclic peptide ligands specific for caix
GB201900525D0 (en) Bicyclic peptide ligands specific for caix
GB201820325D0 (en) Bicyclic peptide ligands specific for psma
GB201820320D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201800593D0 (en) Bicyclic peptide ligands specific for CD38
GB201918495D0 (en) Bicyclic peptide ligands specific for il-46
GB201904632D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201800610D0 (en) Bicylic peptide ligands specific for CD38
GB201918488D0 (en) Bicyclic peptide ligands specific for chymase
GB201818499D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201815684D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201918559D0 (en) Bicyclic peptide ligands specific for IL-17
GB201918558D0 (en) Bicyclic peptide ligands specific for IL-17
GB201918557D0 (en) Bicyclic peptide ligands specific for IL-17
GB201701834D0 (en) Bicyclic peptide ligands specific for CD38
GB201918497D0 (en) Bicyclic peptide ligands specific for klk7
GB201905631D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201904622D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201904621D0 (en) Bicyclic peptide ligands specific for PD-L1

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)